ARDX Ardelyx, Inc.

12.80
-0.6  -4.49%
Previous Close 13.40
Open 13.30
Price To book 2.84
Market Cap 605.45M
Shares 47,301,000
Volume 121,819
Short Ratio 7.28
Av. Daily Volume 179,069

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Onset of action trial data due 2Q 2017.
RDX227675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 data due 1Q 2017.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due later that year.
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. ARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  2. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  3. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  4. Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
  5. Is Ardelyx Inc (ARDX) A Good Stock To Buy Right Now?
  6. ARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  7. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  8. ARDELYX, INC. Financials
  9. Q3 2016 Aurora Diagnostics Inc Earnings Release - After Market Close
  10. Edited Transcript of ARDX earnings conference call or presentation 7-Nov-16 9:05pm GMT
  11. Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress
  12. ARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  13. Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress
  14. Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016
  15. Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016
  16. Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer
  17. Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer
  18. Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
  19. Ardelyx (ARDX) Worth Watching: Stock Rises 6.1% in Session
  20. Ardelyx to Present at Ladenburg Thalmann 2016 Healthcare Conference